High Intensity Focused Ultrasound Combined With Neoadjuvant Chemotherapy For Breast Cancer: A Clinical Research On Sensitization

Objective:To investigate the clinical therapeutic efficacy of breast cancer treated with low power high intensity focused ultrasound (HIFU) in combination with neoadjuvant chemotherapy and to research the changes of cell apoptosis and proliferating cell nuclear antigen (PCNA) expression.Methods:Forty operable female patients with pathologically confirmed breast cancer were divided into HIFU group and control group randomly. Preoperatively, patients in HIFU group were treated with HIFU in combination with adjuvant chemotherapy, and patients in the control group were treated with adjuvant chemotherapy. All patients accepted radical improvement surgery. Pre-treatment and post-treatment, all patients were accepted with liver function, renal function and ultrasonography examinations respectively. And medicamentous adverse reaction was observed. The apoptotic indices (AI) and proliferating cell nuclear antigen (PCNA) in tumor tissues were tested using TdT-mediated dUTP nick end labeling (TUNEL) and SABC immunohistochemical staining respectively.Results:In HIFU group, AI and PCNA expression rate of pretherapy tumor tissues were 0.57±0.39% and 77.78±6.83% respectively, while they were 24.33±5.12% and 30.23±4.51% respectively after HIFU combinated with adjuvant chemotherapy. The differences were significant (P<0.05). In the control group, AI and PCNA expression rate of pretherapy tumor tissues were 0.60±0.21% and 76.34±7.72% respectively, while they were 10.67±3.43% and 55.67±5.62% respectively after adjuvant chemotherapy. The differences were significant (P<0.05). AI and PCNA expression rate changes were more significant in HIFU group than those of the control group (P<0.05).After treatment, the size of primary tumor in HIFU group decreased more obviously than that of control group. The differences were significant (P<0.05).The blood flow of primary tumor was decreased obviously and the clinical stages of most patients were cut down obviously. There was no significance of medicamentous adverse reaction in two groups (P>0.05).Conclusions:Low power HIFU in combination with adjuvant chemotherapy can not only enhance the drug action of chemotherapeutic effects obviously, but also induce breast cancer cell apoptosis and restrain its proliferation in breast cancer, thus it will promote the therapeutic efficacy of breast cancer. Low poweHIFU in combination with neoadjuvant chemotherapy is a safe and effective method to breast cancer.